Symbols / ABT Stock $83.35 -1.20% Abbott Laboratories

Healthcare • Medical Devices • United States • NYQ
ABT (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Medical Devices
CEO Mr. Robert B. Ford
Exch · Country NYQ · United States
Market Cap 145.18B
Enterprise Value 174.40B
Income 6.25B
Sales 45.13B
FCF (ttm) 6.34B
Book/sh 29.89
Cash/sh 4.19
Employees 122,000
Insider 10d —
IPO Mar 17, 1980
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 67.23%
P/E 23.35
Forward P/E 13.75
PEG 1.25
P/S 3.22
P/B 2.79
P/C —
EV/EBITDA 14.85
EV/Sales 3.86
Quick Ratio 0.84
Current Ratio 1.39
Debt/Eq 64.77
LT Debt/Eq —
EPS (ttm) 3.57
EPS next Y 6.06
EPS Growth -19.70%
Revenue Growth 7.80%
EPS Gr Q/Q -18.70%
Rev Gr Q/Q —
Earnings (next) 2026-07-16
Earnings (prior) 2026-04-16
ROA 5.59%
ROE 12.33%
ROIC —
Gross Margin 56.50%
Oper. Margin 13.47%
Profit Margin 13.90%
Shs Outstand 1.74B
Shs Float 1.73B
Insider Own 0.50%
Instit Own 81.17%
Short Float 1.39%
Short Ratio 1.71
Short Interest 21.75M
52W High 139.06
vs 52W High -40.06%
52W Low 81.97
vs 52W Low 1.68%
Beta 0.65
Impl. Vol. 1.56%
Rel Volume 0.02
Avg Volume 12.03M
Volume 261.04K
Target (mean) $118.64
Tgt Median $120.00
Tgt Low $92.00
Tgt High $143.00
# Analysts 25
Recom Buy
Prev Close $84.36
Price $83.35
Change -1.20%
About

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$118.64
Mean price target
2. Current target
$83.35
Latest analyst target
3. DCF / Fair value
$65.53
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$83.35
Low
$92.00
High
$143.00
Mean
$118.64

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-27 reit BTIG Buy → Buy $131
2026-04-20 main Barclays Overweight → Overweight $143
2026-04-17 main Piper Sandler Overweight → Overweight $115
2026-04-17 main Oppenheimer Outperform → Outperform $115
2026-04-17 main RBC Capital Outperform → Outperform $130
2026-04-17 main Benchmark Buy → Buy $120
2026-04-17 main Evercore ISI Group Outperform → Outperform $120
2026-04-17 main B of A Securities Buy → Buy $120
2026-04-17 main Stifel Buy → Buy $120
2026-04-17 reit BTIG Buy → Buy $131
2026-04-09 main Goldman Sachs Buy → Buy $121
2026-04-08 main Barclays Overweight → Overweight $144
2026-04-06 main Evercore ISI Group Outperform → Outperform $134
2026-03-31 main BTIG Buy → Buy $131
2026-03-11 main Citigroup Buy → Buy $136
2026-02-02 main Barclays Overweight → Overweight $142
2026-01-29 up Freedom Broker Hold → Buy $120
2026-01-23 main Citigroup Buy → Buy $140
2026-01-23 main Bernstein Outperform → Outperform $125
2026-01-23 main RBC Capital Outperform → Outperform $135
News
RSS: Latest ABT news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-27 STARKS DANIEL J Director — 10,000 $92.65 $926,537
2026-04-24 O GRADY MICHAEL G Director — 2,286 $0.00 $0
2026-04-24 ROMAN MICHAEL F Director — 2,286 $0.00 $0
2026-04-24 BLOUNT SALLY E Director — 2,286 $0.00 $0
2026-04-24 STARKS DANIEL J Director — 2,286 $0.00 $0
2026-04-24 MCKINSTRY NANCY Director — 2,286 $0.00 $0
2026-04-24 CONROY KEVIN T Director — 2,286 $0.00 $0
2026-04-24 STRATTON JOHN G. Director — 2,286 $0.00 $0
2026-04-24 MCDEW DARREN W Director — 2,286 $0.00 $0
2026-04-24 GONZALEZ PATRICIA PAOLA Director — 2,286 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
44,328.00
+5.67%
41,950.00
+4.59%
40,109.00
-8.12%
43,653.00
Operating Revenue
44,328.00
+5.67%
41,950.00
+4.59%
40,109.00
-8.12%
43,653.00
Cost Of Revenue
19,319.00
+3.28%
18,706.00
+4.07%
17,975.00
-6.10%
19,142.00
Reconciled Cost Of Revenue
17,885.00
+2.99%
17,366.00
+4.00%
16,698.00
-6.65%
17,888.00
Gross Profit
25,009.00
+7.59%
23,244.00
+5.01%
22,134.00
-9.70%
24,511.00
Operating Expense
16,956.00
+3.27%
16,419.00
+4.87%
15,656.00
-3.05%
16,149.00
Research And Development
2,942.00
+3.45%
2,844.00
+3.76%
2,741.00
-5.09%
2,888.00
Selling General And Administration
12,332.00
+5.43%
11,697.00
+6.83%
10,949.00
-2.66%
11,248.00
Total Expenses
36,275.00
+3.27%
35,125.00
+4.44%
33,631.00
-4.70%
35,291.00
Operating Income
8,053.00
+17.99%
6,825.00
+5.36%
6,478.00
-22.53%
8,362.00
Total Operating Income As Reported
8,053.00
+17.99%
6,825.00
+5.36%
6,478.00
-22.53%
8,362.00
EBITDA
12,075.00
+11.91%
10,790.00
+2.33%
10,544.00
-13.08%
12,131.00
Normalized EBITDA
12,025.00
+11.73%
10,763.00
+1.68%
10,585.00
-12.76%
12,133.00
Reconciled Depreciation
3,116.00
-3.17%
3,218.00
-0.77%
3,243.00
-0.73%
3,267.00
EBIT
8,959.00
+18.32%
7,572.00
+3.71%
7,301.00
-17.63%
8,864.00
Total Unusual Items
50.00
+85.19%
27.00
+165.85%
-41.00
-1950.00%
-2.00
Total Unusual Items Excluding Goodwill
50.00
+85.19%
27.00
+165.85%
-41.00
-1950.00%
-2.00
Special Income Charges
—
—
—
—
Net Income
6,524.00
-51.32%
13,402.00
+134.18%
5,723.00
-17.45%
6,933.00
Pretax Income
8,466.00
+20.72%
7,013.00
+5.24%
6,664.00
-19.77%
8,306.00
Net Non Operating Interest Income Expense
-185.00
+13.95%
-215.00
+14.68%
-252.00
+32.80%
-375.00
Interest Expense Non Operating
493.00
-11.81%
559.00
-12.24%
637.00
+14.16%
558.00
Net Interest Income
-185.00
+13.95%
-215.00
+14.68%
-252.00
+32.80%
-375.00
Interest Expense
493.00
-11.81%
559.00
-12.24%
637.00
+14.16%
558.00
Interest Income Non Operating
308.00
-10.47%
344.00
-10.65%
385.00
+110.38%
183.00
Interest Income
308.00
-10.47%
344.00
-10.65%
385.00
+110.38%
183.00
Other Income Expense
598.00
+48.39%
403.00
-7.99%
438.00
+37.30%
319.00
Other Non Operating Income Expenses
548.00
+45.74%
376.00
-21.50%
479.00
+49.22%
321.00
Gain On Sale Of Security
50.00
+85.19%
27.00
+165.85%
-41.00
-1950.00%
-2.00
Tax Provision
1,942.00
+130.40%
-6,389.00
-778.96%
941.00
-31.46%
1,373.00
Tax Rate For Calcs
0.00
+9.05%
0.00
+48.94%
0.00
-14.70%
0.00
Tax Effect Of Unusual Items
11.45
+101.94%
5.67
+198.08%
-5.78
-1648.62%
-0.33
Net Income Including Noncontrolling Interests
6,524.00
-51.32%
13,402.00
+134.18%
5,723.00
-17.45%
6,933.00
Net Income From Continuing Operation Net Minority Interest
6,524.00
-51.32%
13,402.00
+134.18%
5,723.00
-17.45%
6,933.00
Net Income From Continuing And Discontinued Operation
6,524.00
-51.32%
13,402.00
+134.18%
5,723.00
-17.45%
6,933.00
Net Income Continuous Operations
6,524.00
-51.32%
13,402.00
+134.18%
5,723.00
-17.45%
6,933.00
Net Income Discontinuous Operations
—
—
—
0.00
Normalized Income
6,485.45
-51.53%
13,380.67
+132.38%
5,758.22
-16.96%
6,934.67
Net Income Common Stockholders
6,524.00
-51.32%
13,402.00
+134.18%
5,723.00
-17.45%
6,933.00
Diluted EPS
3.72
-51.31%
7.64
+134.36%
3.26
-16.62%
3.91
Basic EPS
3.76
-51.46%
7.74
+134.50%
3.30
-17.28%
3.99
Basic Average Shares
1,736.60
+0.28%
1,731.70
-0.14%
1,734.08
-0.21%
1,737.80
Diluted Average Shares
1,749.00
+0.06%
1,748.00
-0.06%
1,749.00
-0.85%
1,764.00
Diluted NI Availto Com Stockholders
6,524.00
-51.32%
13,402.00
+134.18%
5,723.00
-17.45%
6,933.00
Amortization
1,682.00
-10.44%
1,878.00
-4.48%
1,966.00
-2.33%
2,013.00
Amortization Of Intangibles Income Statement
1,682.00
-10.44%
1,878.00
-4.48%
1,966.00
-2.33%
2,013.00
Depreciation Amortization Depletion Income Statement
1,682.00
-10.44%
1,878.00
-4.48%
1,966.00
-2.33%
2,013.00
Depreciation And Amortization In Income Statement
1,682.00
-10.44%
1,878.00
-4.48%
1,966.00
-2.33%
2,013.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
86,713.00
+6.51%
81,414.00
+11.20%
73,214.00
-1.64%
74,438.00
Current Assets
25,996.00
+9.89%
23,656.00
+4.35%
22,670.00
-10.13%
25,224.00
Cash Cash Equivalents And Short Term Investments
8,939.00
+12.20%
7,967.00
+9.45%
7,279.00
-28.43%
10,170.00
Cash And Cash Equivalents
8,522.00
+11.90%
7,616.00
+10.44%
6,896.00
-30.22%
9,882.00
Other Short Term Investments
417.00
+18.80%
351.00
-8.36%
383.00
+32.99%
288.00
Receivables
10,569.00
+11.31%
9,495.00
+7.64%
8,821.00
-0.68%
8,881.00
Accounts Receivable
7,929.00
+14.50%
6,925.00
+5.48%
6,565.00
+5.58%
6,218.00
Gross Accounts Receivable
8,419.00
+14.33%
7,364.00
+5.06%
7,009.00
+4.33%
6,718.00
Allowance For Doubtful Accounts Receivable
-490.00
-11.62%
-439.00
+1.13%
-444.00
+11.20%
-500.00
Other Receivables
2,640.00
+2.72%
2,570.00
+13.92%
2,256.00
-15.28%
2,663.00
Inventory
6,488.00
+4.75%
6,194.00
-5.72%
6,570.00
+6.43%
6,173.00
Raw Materials
1,608.00
-2.78%
1,654.00
-8.97%
1,817.00
+7.64%
1,688.00
Work In Process
904.00
+7.62%
840.00
+4.09%
807.00
+18.68%
680.00
Finished Goods
3,976.00
+7.46%
3,700.00
-6.23%
3,946.00
+3.71%
3,805.00
Prepaid Assets
—
—
—
—
Total Non Current Assets
60,717.00
+5.12%
57,758.00
+14.27%
50,544.00
+2.70%
49,214.00
Net PPE
11,816.00
+10.87%
10,658.00
+4.96%
10,154.00
+10.83%
9,162.00
Gross PPE
25,222.00
+10.91%
22,740.00
+3.68%
21,933.00
+8.51%
20,212.00
Accumulated Depreciation
-13,406.00
-10.96%
-12,082.00
-2.57%
-11,779.00
-6.60%
-11,050.00
Properties
0.00
0.00
0.00
0.00
Land And Improvements
541.00
+2.46%
528.00
-0.19%
529.00
+3.52%
511.00
Buildings And Improvements
4,543.00
+7.99%
4,207.00
+1.11%
4,161.00
+2.66%
4,053.00
Machinery Furniture Equipment
—
—
—
—
Construction In Progress
2,567.00
+3.18%
2,488.00
+20.54%
2,064.00
+39.08%
1,484.00
Other Properties
17,571.00
+13.24%
15,517.00
+2.23%
15,179.00
+7.17%
14,164.00
Goodwill And Other Intangible Assets
29,561.00
-0.65%
29,755.00
-8.43%
32,494.00
-2.28%
33,253.00
Goodwill
24,035.00
+4.01%
23,108.00
-2.41%
23,679.00
+3.86%
22,799.00
Other Intangible Assets
5,526.00
-16.86%
6,647.00
-24.59%
8,815.00
-15.68%
10,454.00
Investments And Advances
918.00
+3.61%
886.00
+10.89%
799.00
+4.31%
766.00
Other Investments
321.00
-3.60%
333.00
+36.48%
244.00
+17.31%
208.00
Non Current Deferred Assets
—
—
—
6,033.00
Non Current Deferred Taxes Assets
—
—
—
6,033.00
Other Non Current Assets
18,422.00
+11.93%
16,459.00
+131.91%
7,097.00
+17.64%
6,033.00
Total Liabilities Net Minority Interest
33,942.00
+1.28%
33,513.00
-2.54%
34,387.00
-8.38%
37,533.00
Current Liabilities
16,496.00
+16.52%
14,157.00
+2.28%
13,841.00
-10.64%
15,489.00
Payables And Accrued Expenses
13,463.00
+6.37%
12,657.00
-0.81%
12,761.00
-3.60%
13,238.00
Payables
6,588.00
+2.39%
6,434.00
+0.66%
6,392.00
-1.28%
6,475.00
Accounts Payable
4,240.00
+1.07%
4,195.00
-2.33%
4,295.00
-6.77%
4,607.00
Other Payable
682.00
+9.82%
621.00
-4.46%
650.00
+1.88%
638.00
Dividends Payable
1,097.00
+7.13%
1,024.00
+7.23%
955.00
+7.67%
887.00
Current Accrued Expenses
6,875.00
+10.48%
6,223.00
-2.29%
6,369.00
-5.83%
6,763.00
Employee Benefits
2,125.00
+13.03%
1,880.00
-4.28%
1,964.00
+10.09%
1,784.00
Total Tax Payable
569.00
-4.21%
594.00
+20.73%
492.00
+43.44%
343.00
Income Tax Payable
569.00
-4.21%
594.00
+20.73%
492.00
+43.44%
343.00
Current Debt And Capital Lease Obligation
3,033.00
+102.20%
1,500.00
+38.89%
1,080.00
-52.02%
2,251.00
Current Debt
3,033.00
+102.20%
1,500.00
+38.89%
1,080.00
-52.02%
2,251.00
Total Non Current Liabilities Net Minority Interest
17,446.00
-9.87%
19,356.00
-5.79%
20,546.00
-6.80%
22,044.00
Long Term Debt And Capital Lease Obligation
10,827.00
-19.92%
13,521.00
-7.06%
14,548.00
-5.93%
15,465.00
Long Term Debt
9,896.00
-21.62%
12,625.00
-7.16%
13,599.00
-6.36%
14,522.00
Long Term Capital Lease Obligation
931.00
+3.91%
896.00
-5.58%
949.00
+0.64%
943.00
Non Current Pension And Other Postretirement Benefit Plans
2,125.00
+13.03%
1,880.00
-4.28%
1,964.00
+10.09%
1,784.00
Tradeand Other Payables Non Current
1,397.00
+63.01%
857.00
-20.65%
1,080.00
—
Non Current Deferred Liabilities
559.00
+9.18%
512.00
-9.86%
568.00
-42.68%
991.00
Non Current Deferred Taxes Liabilities
559.00
+9.18%
512.00
-9.86%
568.00
-42.68%
991.00
Other Non Current Liabilities
2,538.00
-1.86%
2,586.00
+8.38%
2,386.00
-37.28%
3,804.00
Stockholders Equity
52,130.00
+9.37%
47,664.00
+23.47%
38,603.00
+5.23%
36,686.00
Common Stock Equity
52,130.00
+9.37%
47,664.00
+23.47%
38,603.00
+5.23%
36,686.00
Capital Stock
25,527.00
+1.49%
25,153.00
+1.14%
24,869.00
+0.65%
24,709.00
Common Stock
25,527.00
+1.49%
25,153.00
+1.14%
24,869.00
+0.65%
24,709.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
1,996.80
+0.27%
1,991.47
+0.18%
1,987.88
+0.07%
1,986.52
Ordinary Shares Number
1,736.60
+0.28%
1,731.70
-0.14%
1,734.08
-0.21%
1,737.80
Treasury Shares Number
260.20
+0.16%
259.77
+2.35%
253.81
+2.04%
248.72
Retained Earnings
49,781.00
+5.33%
47,261.00
+25.85%
37,554.00
+6.52%
35,257.00
Gains Losses Not Affecting Retained Earnings
-6,001.00
+24.10%
-7,906.00
-0.85%
-7,839.00
+2.63%
-8,051.00
Treasury Stock
17,177.00
+1.98%
16,844.00
+5.40%
15,981.00
+4.94%
15,229.00
Minority Interest
641.00
+170.46%
237.00
+5.80%
224.00
+2.28%
219.00
Other Equity Adjustments
-6,001.00
+24.10%
-7,906.00
-0.85%
-7,839.00
+2.63%
-8,051.00
Total Equity Gross Minority Interest
52,771.00
+10.17%
47,901.00
+23.37%
38,827.00
+5.21%
36,905.00
Total Capitalization
62,026.00
+2.88%
60,289.00
+15.49%
52,202.00
+1.94%
51,208.00
Working Capital
9,500.00
+0.01%
9,499.00
+7.59%
8,829.00
-9.31%
9,735.00
Invested Capital
65,059.00
+5.29%
61,789.00
+15.97%
53,282.00
-0.33%
53,459.00
Total Debt
13,860.00
-7.73%
15,021.00
-3.88%
15,628.00
-11.79%
17,716.00
Net Debt
4,407.00
-32.29%
6,509.00
-16.37%
7,783.00
+12.94%
6,891.00
Capital Lease Obligations
931.00
+3.91%
896.00
-5.58%
949.00
+0.64%
943.00
Net Tangible Assets
22,569.00
+26.02%
17,909.00
+193.16%
6,109.00
+77.95%
3,433.00
Tangible Book Value
22,569.00
+26.02%
17,909.00
+193.16%
6,109.00
+77.95%
3,433.00
Available For Sale Securities
597.00
+7.96%
553.00
-0.36%
555.00
-0.54%
558.00
Investmentin Financial Assets
597.00
+7.96%
553.00
-0.36%
555.00
-0.54%
558.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
9,566.00
+11.78%
8,558.00
+17.86%
7,261.00
-24.21%
9,581.00
Cash Flow From Continuing Operating Activities
9,566.00
+11.78%
8,558.00
+17.86%
7,261.00
-24.21%
9,581.00
Net Income From Continuing Operations
6,524.00
-51.32%
13,402.00
+134.18%
5,723.00
-17.45%
6,933.00
Depreciation Amortization Depletion
3,116.00
-3.17%
3,218.00
-0.77%
3,243.00
-0.73%
3,267.00
Depreciation
1,434.00
+7.01%
1,340.00
+4.93%
1,277.00
+1.83%
1,254.00
Amortization Cash Flow
1,682.00
-10.44%
1,878.00
-4.48%
1,966.00
-2.33%
2,013.00
Depreciation And Amortization
3,116.00
-3.17%
3,218.00
-0.77%
3,243.00
-0.73%
3,267.00
Amortization Of Intangibles
1,682.00
-10.44%
1,878.00
-4.48%
1,966.00
-2.33%
2,013.00
Stock Based Compensation
664.00
-1.34%
673.00
+4.50%
644.00
-5.99%
685.00
Operating Gains Losses
65.00
-86.51%
482.00
+282.54%
126.00
-41.40%
215.00
Gain Loss On Investment Securities
65.00
-86.51%
482.00
+282.54%
126.00
-41.40%
215.00
Change In Working Capital
-803.00
+91.29%
-9,217.00
-272.40%
-2,475.00
-62.94%
-1,519.00
Change In Receivables
-652.00
+5.64%
-691.00
-94.10%
-356.00
-423.53%
-68.00
Changes In Account Receivables
-652.00
+5.64%
-691.00
-94.10%
-356.00
-423.53%
-68.00
Change In Inventory
195.00
+436.21%
-58.00
+75.00%
-232.00
+83.58%
-1,413.00
Change In Prepaid Assets
-1,295.00
-62.69%
-796.00
-46.86%
-542.00
-622.67%
-75.00
Change In Payables And Accrued Expense
949.00
+112.37%
-7,672.00
-470.41%
-1,345.00
-3735.14%
37.00
Change In Payable
949.00
+112.37%
-7,672.00
-470.41%
-1,345.00
-3735.14%
37.00
Change In Account Payable
954.00
+167.98%
356.00
+146.84%
-760.00
-280.95%
420.00
Change In Other Working Capital
—
—
-585.00
-52.74%
-383.00
Investing Cash Flow
-2,422.00
-3.59%
-2,338.00
+25.38%
-3,133.00
-80.06%
-1,740.00
Cash Flow From Continuing Investing Activities
-2,422.00
-3.59%
-2,338.00
+25.38%
-3,133.00
-80.06%
-1,740.00
Net PPE Purchase And Sale
-2,171.00
+1.63%
-2,207.00
-0.23%
-2,202.00
-23.92%
-1,777.00
Purchase Of PPE
-2,171.00
+1.63%
-2,207.00
-0.23%
-2,202.00
-23.92%
-1,777.00
Capital Expenditure
-2,171.00
+1.63%
-2,207.00
-0.23%
-2,202.00
-23.92%
-1,777.00
Net Investment Purchase And Sale
-164.00
-16.31%
-141.00
-21.55%
-116.00
-251.52%
-33.00
Purchase Of Investment
-167.00
+1.18%
-169.00
-6.29%
-159.00
+14.05%
-185.00
Sale Of Investment
3.00
-89.29%
28.00
-34.88%
43.00
-71.71%
152.00
Net Business Purchase And Sale
-105.00
-10600.00%
1.00
+100.12%
-837.00
-1843.75%
48.00
Purchase Of Business
-105.00
0.00
+100.00%
-877.00
0.00
Net Other Investing Changes
18.00
+100.00%
9.00
-59.09%
22.00
+0.00%
22.00
Financing Cash Flow
-6,309.00
-16.75%
-5,404.00
+23.79%
-7,091.00
+7.14%
-7,636.00
Cash Flow From Continuing Financing Activities
-6,309.00
-16.75%
-5,404.00
+23.79%
-7,091.00
+7.14%
-7,636.00
Net Issuance Payments Of Debt
-1,614.00
-200.56%
-537.00
+78.30%
-2,475.00
-254.08%
-699.00
Issuance Of Debt
5.00
-97.76%
223.00
+11050.00%
2.00
-71.43%
7.00
Repayment Of Debt
-1,504.00
-127.88%
-660.00
+73.58%
-2,498.00
-231.74%
-753.00
Long Term Debt Issuance
5.00
-97.76%
223.00
+11050.00%
2.00
-71.43%
7.00
Long Term Debt Payments
-1,504.00
-127.88%
-660.00
+73.58%
-2,498.00
-231.74%
-753.00
Net Long Term Debt Issuance
-1,499.00
-243.02%
-437.00
+82.49%
-2,496.00
-234.58%
-746.00
Net Short Term Debt Issuance
-115.00
-15.00%
-100.00
-576.19%
21.00
-55.32%
47.00
Net Common Stock Issuance
-893.00
+31.04%
-1,295.00
-5.54%
-1,227.00
+67.67%
-3,795.00
Common Stock Payments
-893.00
+31.04%
-1,295.00
-5.54%
-1,227.00
+67.67%
-3,795.00
Common Stock Dividend Paid
-4,116.00
-7.30%
-3,836.00
-7.87%
-3,556.00
-7.46%
-3,309.00
Cash Dividends Paid
-4,116.00
-7.30%
-3,836.00
-7.87%
-3,556.00
-7.46%
-3,309.00
Repurchase Of Capital Stock
-893.00
+31.04%
-1,295.00
-5.54%
-1,227.00
+67.67%
-3,795.00
Proceeds From Stock Option Exercised
396.00
+50.00%
264.00
+58.08%
167.00
+0.00%
167.00
Net Other Financing Charges
-82.00
—
—
—
Changes In Cash
835.00
+2.33%
816.00
+127.54%
-2,963.00
-1545.37%
205.00
Effect Of Exchange Rate Changes
71.00
+173.96%
-96.00
-317.39%
-23.00
+81.15%
-122.00
Beginning Cash Position
7,616.00
+10.44%
6,896.00
-30.22%
9,882.00
+0.85%
9,799.00
End Cash Position
8,522.00
+11.90%
7,616.00
+10.44%
6,896.00
-30.22%
9,882.00
Free Cash Flow
7,395.00
+16.44%
6,351.00
+25.54%
5,059.00
-35.17%
7,804.00
Interest Paid Supplemental Data
545.00
-9.77%
604.00
-8.76%
662.00
+17.58%
563.00
Income Tax Paid Supplemental Data
1,933.00
+12.19%
1,723.00
+16.81%
1,475.00
-20.87%
1,864.00
Change In Income Tax Payable
-5.00
+99.94%
-8,028.00
-1272.31%
-585.00
-52.74%
-383.00
Change In Tax Payable
-5.00
+99.94%
-8,028.00
-1272.31%
-585.00
-52.74%
-383.00
Sale Of Business
0.00
-100.00%
1.00
-97.50%
40.00
-16.67%
48.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category